Pergamum estimates its products to have a combined peak sales potential of more than EUR 1 billion. The company plans to achieve Phase II data in up to four of its programs until 2013.
Pergamum’s strategy is to initiate partnering discussions for development programs once they have achieved clinical proof of concept in a pilot or full Phase II study. Targeted partners are mid to large-size pharmaceutical companies. Pergamum also evaluates other strategic partnering opportunities as they occur, and welcomes interest from potential partners in any ongoing project.
For details regarding business development opportunities, please contact our team in Stockholm at +46 (0)8 470 37 40, or by filling out our contact form.
* 12-15% CAGR; Data from Datamonitor, 2010